Brii Biosciences Limited (BRIBF)
OTCMKTS
· Delayed Price · Currency is USD
0.3042
+0.0042 (1.40%)
At close: Mar 31, 2025
Brii Biosciences Revenue
In the year 2024, Brii Biosciences had annual revenue of 54.29M CNY, down -3.61%. Brii Biosciences had revenue of 32.13M in the half year ending December 31, 2024, a decrease of -65.96%.
Revenue
54.29M CNY
Revenue Growth
-3.61%
P/S Ratio
24.56
Revenue / Employee
553.94K CNY
Employees
98
Market Cap
182.65M USD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Glass House Brands | 200.90M |
Northwest Biotherapeutics | 1.38M |
Elite Pharmaceuticals | 70.00M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Silence Therapeutics | 43.26M |
Brii Biosciences News
- 4 weeks ago - Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification - PRNewsWire
- 4 months ago - Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study - PRNewsWire
- 5 months ago - Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA - PRNewsWire
- 11 months ago - Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024 - PRNewsWire
- 1 year ago - Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer - PRNewsWire
- 1 year ago - Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023 - PRNewsWire
- 1 year ago - Brii Biosciences Provides Latest Clinical Development and Corporate Updates - PRNewsWire
- 2 years ago - Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693 - PRNewsWire